Belinostat
Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
Corvus Pharmaceuticals, Inc.Small moleculePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Nodal T-Follicular Helper Cell Lymphoma, Follicular Type cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pralatrexate Corvus Pharmaceuticals, Inc. | Phase 3 | BB |
Soquelitinib Corvus Pharmaceuticals, Inc. | Phase 3 | B |
Nivestim City of Hope Medical Center | Phase 3 | B |
Pembrolizumab Northwestern University | Phase 2 | B |
Adriamycin City of Hope Medical Center | Phase 2 | B |
View all 18 →
Same molecule, other indications
Belinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →